Ritodrine Hydrochloride

Pharmacological studies have shown that ritodrine hydrochloride acts on the beta 2 receptors of uterine smooth muscle, thereby inhibiting the contraction frequency and intensity of uterine smooth muscle. It is an effective drug for oral, intramuscular and intravenous injection to prolong pregnancy and prevent premature birth. Carcinogenicity, teratogenicity, and effects on fertility: Rats were orally administered ritodrine hydrochloride at 1 mg/kg, 10 mg/kg and 150 mg/kg daily for 82 weeks. Benign and malignant tumors were found in all dose groups. Since there was no significant difference between the treatment group and the control group and there was no dose-related trend, it was inferred that there was no sign of carcinogenicity. In the reproduction study of rats and rabbits, the results showed that ritodrine hydrochloride had no effect on fertility.

Ritodrine hydrochloride

This product is white round tablets.

Prevent premature birth after 20 weeks of pregnancy. The effectiveness and safety of this product when the cervical opening is greater than 4 cm or more than 80% open has not yet been established.

Diagnosed with premature delivery and suitable for this product, initially use intravenous drip followed by oral maintenance treatment, closely monitor uterine contraction and side effects to determine the best dosage. Oral treatment begins 30 minutes before the end of intravenous drip, the initial 24-hour oral dose is 1 tablet (10 mg) every 2 hours, and thereafter 1-2 tablets (10-20 mg) every 4-6 hours, with a total daily dose of no more than 12 tablets (120 mg). The commonly used daily maintenance dose is between 80-120 mg (8-12 tablets), administered in equal doses. Oral medication can be continued as long as the doctor deems it necessary to prolong the pregnancy. Or follow the doctor's advice.

The adverse reactions of this product are related to the b; sympathetic nerve action and can usually be controlled by adjusting the dose. Intravenous infusion often causes an increase in the heart rate of pregnant women and fetuses. For healthy pregnant women, the heart rate should be avoided to exceed 140 beats/minute. Appropriate reduction of the dose or cessation of infusion will quickly return to normal. Serious adverse reactions: pulmonary edema, pulmonary edema combined with heart failure, leukopenia, agranulocytosis, arrhythmia, in the case of multiple pregnancies, there are reports of arrhythmia turning into cardiac arrest immediately after the administration of anesthetics, rhabdomyolysis (muscle pain, weakness, CPK increase, increased myoglobin in blood and urine), neonatal intestinal occlusion, neonatal ventricular septal hypertrophy, low serum potassium caused by beta; 2 receptor agonists, shock, jaundice, Stenvens-Johnson syndrome. Other adverse reactions: Cardiovascular system: supraventricular tachycardia, palpitations, tachycardia, sometimes facial flushing, chest pain, dyspnea, rare electrocardiogram abnormalities (ST-T abnormalities), facial pain. Fetal tachycardia and arrhythmia. Liver: Sometimes there is damage to liver function (increase in GOT, GPT, etc.). Blood system: Rarely thrombocytopenia. Psychoneural system: Sometimes there is tremor, numbness, headache, heat in the extremities, weakness, rarely sweating, and dizziness. Digestive system: Sometimes there is nausea, vomiting, constipation, and swelling of the salivary glands with increased amylase. Allergies: Sometimes there is rash, itching, rarely erythema, and swelling. Administration site: Sometimes there is vascular pain and phlebitis. Others: Transient increase in blood sugar, increase in CPK, sometimes changes in urine sugar, fever, and rarely cold sweats. Pregnant women who have used b; sympathomimetic agents have symptoms of hypocalcemia, hypoglycemia, and intestinal obstruction in their babies, but these are rare.

This product is contraindicated for use in pregnant women who are less than 20 weeks pregnant. It is also contraindicated for use in situations where prolonged pregnancy poses a risk to the pregnant woman and the fetus, including: 1. Heavy bleeding before delivery for any reason, especially placenta previa and placental abruption. 2. Eclampsia and severe preeclampsia. 3. Fetal death in the womb. 4. Chorioamnionitis. 5. Pregnant women with heart disease and conditions that endanger heart function. 6. Pulmonary hypertension. 7. Pregnant women with hyperthyroidism. 8. Uncontrolled diabetes. 9. Severe hypertension. 10. Allergic to any ingredient in this product.

1 Avoid using it at the same time with beta-receptor agonists and inhibitors. 2 Simultaneous use of corticosteroids may lead to pulmonary edema. 3 The following drugs used at the same time may aggravate the cardiovascular effects, especially arrhythmias or hypotension: ① Magnesium sulfate ② Diazoxide ③ Pethidine ④ Strong anesthetics 4 Hypertension may occur in the presence of parasympathetic blockers such as atropine. 5 When used simultaneously with other parasympathetic amines, the cardiovascular effects are enhanced. But this can be avoided as long as there is enough time interval. Because 90% of ritodrine is excreted from the body within 24 hours of administration. 6 For anesthetics used in surgery, it should be considered that the effects on patients with hypotension may be enhanced.

Store at room temperature (preferably below 30°C).

Guangdong Xianqiang Pharmaceuticle Co., Ltd.

• Founded in:

  2002-09-23

• Address:

  No. 6 Industrial Avenue, Conghua Economic Development Zone, Guangzhou

• Tax NO.:

  91440101739742301K

• Registered Funds:

  223.9 million yuan

• Website:

  Log in to view

• Email:

  Log in to view